Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
TELO | TSXV | CAD | Delayed | |
TDSGF | OTC Markets | USD | Delayed | |
TELO | CBOE Canada | CAD | Real-time |
For the nine months ended 31 March 2022, Telo Genomics Corp revenues was not reported. Net loss increased from C$721K to C$1.5M. Higher net loss reflects Selling/General/Admin. Expense increase of 98% to C$728K (expense), Research and development increase of 77% to C$730K (expense). Basic Earnings per Share excluding Extraordinary Items remained flat at -C$0.02.
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0 | 0 |
Gross Profit | ||||
Operating Income | -0.51 | -0.46 | -0.48 | -0.35 |
Net Income | -0.51 | -0.46 | -0.48 | -0.35 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Assets | 3.32 | 3.74 | 3.93 | 3.84 |
Total Liabilities | 0.09 | 0.08 | 0.21 | 0.15 |
Total Equity | 3.23 | 3.66 | 3.72 | 3.69 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | -1.35 | -0.91 | -0.32 | -1.1 |
Cash From Investing Activities | -0 | -0 | -0.01 | |
Cash From Financing Activities | 0.88 | 0.88 | 0.49 | 3.83 |
Net Change in Cash | -0.47 | -0.03 | 0.17 | 2.72 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review